Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9P0J0

UPID:
NDUAD_HUMAN

ALTERNATIVE NAMES:
Cell death regulatory protein GRIM-19; Complex I-B16.6; Gene associated with retinoic and interferon-induced mortality 19 protein; NADH-ubiquinone oxidoreductase B16.6 subunit

ALTERNATIVE UPACC:
Q9P0J0; B4DF76; K7EK58; Q6PKI0; Q9H2L3; Q9Y327

BACKGROUND:
The protein NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13, known by alternative names such as GRIM-19, is integral to mitochondrial function and cellular energy production. It assists in transferring electrons within the mitochondrial membrane, and has roles in cell death pathways, immune responses, and inflammation regulation.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in Hurthle cell thyroid carcinoma and mitochondrial complex I deficiency, GRIM-19 represents a promising avenue for drug discovery. Targeting GRIM-19 could lead to innovative treatments for these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.